spacer
home > > spring 2004 > 21st century, in cns, oncology and hiv clinical trials: current trends and future prospects
PUBLICATIONS


21st Century, in CNS, Oncology and HIV Clinical Trials: Current Trends and Future Prospects

Canvas opinion around the medical and scientific communities as to the therapeutic areas presenting the greatest challenges for the pharmaceutical industry in the 21st Century, and the chances are that CNS disease (a term covering a broad spectrum of pathologies), oncology and HIV infection will be at the top of many people's lists. Whilst some significant advances have occurred in these therapeutic areas over the last decade, the continuing morbidity and mortality associated with a diagnosis in these areas confirms the need for new therapies.

Over the last decade the explosion of biotechnology has provided a barrage of new targets and technologies. Completion of the human genome project should only accelerate this in the future. This has placed an increasing burden on the clinical development process, with more complex and costly trials, and the need to validate new endpoints. Companies need to look continually for more efficient and effective methodologies in order to select only the most promising candidates to take into the clinic to maximise their return on investment. In this article we will highlight some of the challenges facing decision-makers as they plan clinical trial programmes in these areas, and the prospects for future therapeutic advances.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Phil Collis, VP Scientific Affairs and Professor Gordon McVie, Oncology Advisor at Inveresk

Phil Collis has been Vice President of Scientific Affairs, Global Clinical at Inveresk Research in North Carolina since October 2003. He is principally responsible for international strategic client liaison and consulting on clinical development plans, regulatory strategy and feasibility analysis. Prior to this, he was Director, and then Vice President of International Operations for PharmaResearch Corporation in the UK. He has also worked as a Principal Clinical Research Scientist, Senior Clinical Research Scientist and Clinical Research Scientist for Glaxo Wellcome Research and Development. Phil gained his PhD in Molecular Genetics and also studied for his BSc (Hons) in Biochemistry at the University of London. He is an Associate of the Royal College of Science and a Member of the Institute for Clinical Research (ICR), the International AIDS Society, British HIV Association and the Drug Industry Association (DIA).

Professor Gordon McVie MD, FRCP, FRCPS, FRCSE, FMedSci, DSc(Hon) is widely regarded as a leading international authority in the research and treatment of cancer. He is currently Director of Cancer Intelligence, an advisory body to biotechnology and pharmaceutical companies, investors, the media and cancer patients. He is a Visiting Professor at Glasgow University, Scotland; honorary Consultant in Medical Oncology at the Welsh Cancer Institute, Cardiff; Clinical Research Director at the European Institute of Oncology, Milan; and Oncology Advisor to Inveresk. Previously Professor McVie was Chief Executive of the Cancer Research Campaign (CRC). He has authored almost 300 peer-reviewed articles, contributed to over 35 books and is currently European Editor for the US Journal of the National Cancer Institute.
spacer
Phil Collis
spacer
spacer
spacer
Gordon McVie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pharmaceutical companies go temporary to overcome pandemic challenges

Fast-tracking clinical trials, optimising energy intensive processes and improving yield are three ways in which temporary equipment is helping pharmaceutical companies amid the COVID-19 pandemic.
More info >>

White Papers

Recommendations Sourcing Human Biospecimens

BioIVT

The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice. The use of human biospecimens in research supports these principles with legal and ethical regulations - the most important of which is permission.(1) This permission may come directly from the donor or granted by others with authorization to protect the interests of biospecimen donors.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement